Evotec (ETR:EVT) Stock Price Crosses Above 50-Day Moving Average – Should You Sell?

Evotec SE (ETR:EVT)’s stock price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of €4.83 and traded as high as €5.23. Evotec shares last traded at €5.23, with a volume of 605,744 shares trading hands.

Evotec Price Performance

The firm has a market cap of $929.58 million, a P/E ratio of -5.42, a P/E/G ratio of 0.98 and a beta of 1.30. The company has a quick ratio of 2.97, a current ratio of 1.68 and a debt-to-equity ratio of 55.38. The business’s 50 day moving average is €4.84 and its two-hundred day moving average is €5.38.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.